Physician profile
Nancy Vasquez
NPI 1982018255
$5,875.88
in general payments reported to CMS, 2019-2025
18 companies · $742 in 2025
The $742 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $611 · 2022: $1,109 · 2023: $1,702 · 2024: $1,712 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,156.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $1,379.56 | 2021-2025 | Valtoco |
| Ironshore Pharmaceuticals INC. | $1,113.03 | 2021-2024 | Jornay Pm |
| Ucb, INC. | $1,059.70 | 2021-2025 | Briviact, Nayzilam |
| Supernus Pharmaceuticals, INC. | $666.73 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $352.80 | 2021-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $215.02 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $183.27 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $145.70 | 2023-2024 | Aptiom |
| Eisai INC. | $137.12 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.93 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $119.34 | 2021-2022 | |
| Otter Pharmaceuticals, LLC | $111.80 | 2024-2025 | Sympazan |
| Sk Life Science, INC. | $100.53 | 2021-2024 | |
| Catalyst Pharmaceuticals, INC. | $56.14 | 2024 | |
| Immedica Pharma US, INC. | $42.37 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $22.27 | 2022 | |
| Aquestive Therapeutics, INC. | $21.91 | 2022 | |
| Tris Pharma INC | $20.66 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Vasquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.